This refresh
Data-driven refresh June 26, 2026. The Top Picks are the Bull Rankings quality-growth screen — strong, growing businesses with durable returns at a fair price (PEG / EV-EBIT vs sector, ROIC, free cash flow), ranked across a 5224-ticker universe covering every US-listed common stock on NYSE, NASDAQ, NYSE American, and NYSE Arca (2551 passed the market-cap / liquidity screen; financials route to a separate card). Fundamentals from Yahoo Finance quoteSummary reconciled with as-reported SEC EDGAR filings; narrative authored by Groq (with Gemini and data-driven fallbacks).
Top Picks — quality compounders at a fair price
1. INCY — Incyte Corporation · score 90.5
Biotechnology · price $107.53 · 1Y $110.26 · 5Y $161.43 · 10Y $239.47
FCF $1.4b C+ · Rev +21.2% A- · D/E 0.01 A · P/E 15.2x A- · PEG 0.36 A
Why now. Incyte Corporation is a compelling growth story driven by its robust product lineup, including JAKAFI and ICLUSIG, with a 21.2% revenue growth rate and a 26.7% profit margin, all while maintaining a 0.36 PEG ratio, indicating that the growth is reasonably priced. The company's ability to compound growth persists due to its strong commercialization capabilities and a debt-to-equity ratio of 0.01, providing ample room for strategic investments. The crux of this thesis rests on Incyte's ability to continue delivering innovative therapeutics and leveraging its existing products to drive further growth.
Moat. Incyte's durable edge stems from its portfolio of differentiated therapeutics, such as MONJUVI/MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma, which benefits from high barriers to entry due to the complexity of developing and commercializing such treatments. The company's 25.5% ROE is a testament to its pricing power, derived from category leadership in specific disease areas. This advantage is further reinforced by the high switching costs for patients and healthcare providers, making it difficult for competitors to quickly replicate Incyte's market position.
Risk. The bear case against Incyte centers on the potential for increased competition in the biopharmaceutical space, particularly from generic versions of its drugs or new innovative therapies that could erode the market share of JAKAFI and other key products. With a 15.2 P/E ratio, there is a risk that the stock could be overvalued if growth slows down. A concrete signal that would confirm the bear case is a significant decline in Incyte's revenue growth rate or a failure to successfully commercialize its pipeline products, which would break the bull thesis and suggest that the company's growth trajectory is not as robust as anticipated.
Horizon. 1-3 yr $110.26 (analyst consensus (n=23)) — fundamentals + valuation re-rating. 5 yr $161.43 at ~8% CAGR — compounding case rests on the competitive position widening. 10 yr $239.47 if current growth sustains into durable earnings power.
2. DOCS — Doximity, Inc. · score 90.4
Health Information Services · price $19.85 · 1Y $25.42 · 5Y $37.22 · 10Y $55.21
FCF $326m C · Rev +13.1% B+ · D/E 0.01 A- · P/E 20.3x B+ · PEG 0.59 A-
Why now. Doximity's bull case rests on its ability to compound growth through its personalized newsfeed and workflow tools like Ask and Scribe, with a 20.3 P/E ratio, 0.59 PEG ratio, and 30.4% profit margin, all of which suggest a high-quality growth franchise. The company's $326m in free cash flow and 13.1% revenue growth rate further support this thesis, which ultimately hinges on the persistence of its 20.6% ROE.
Moat. Doximity's durable edge stems from its HIPAA-compliant AI assistant, Ask, and its clinical discussions platform, which create a network effect among medical professionals, making it difficult for competitors to replicate. The company's 20.6% ROE can be attributed to its pricing power from category leadership in the medical professional networking space, which is further reinforced by its 0.01 debt-to-equity ratio, indicating a strong balance sheet.
Risk. The bear case against Doximity centers on its high 1.29 beta and $3.6b market capitalization, which may make the stock volatile and sensitive to market downturns. Additionally, the company's 5.6 P/S ratio is relatively high, which could indicate overvaluation. If the company's revenue growth rate were to decelerate significantly, it could confirm the bear case and break the bull thesis, particularly if the 13.1% revenue growth rate were to slow down substantially.
Horizon. 1-3 yr $25.42 (analyst consensus (n=19)) — fundamentals + valuation re-rating. 5 yr $37.22 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $55.21 if current growth sustains into durable earnings power.
3. INTU — Intuit Inc. · score 89.8
Software - Application · price $255.07 · 1Y $488.17 · 5Y $714.73 · 10Y $1,060
FCF $7.8b B+ · Rev +15.6% B+ · D/E 0.33 B · P/E 15.6x A- · PEG 0.68 A-
Why now. Intuit's bull case rests on its ability to compound growth through its QuickBooks services and Mailchimp marketing automation, with a 15.6% revenue growth rate and $7.8b in free cash flow, all while maintaining a 21.9% profit margin, making it an attractive growth investment. The company's 0.68 PEG ratio suggests its growth is undervalued relative to its price. The crux of this thesis is that Intuit can sustain its revenue growth through its diverse product offerings and expanding customer base.
Moat. Intuit's durable edge comes from its category leadership in financial and business management online services, particularly through QuickBooks, which provides a high switching cost for its small and mid-market business customers. The company's 22.2% ROE is a result of its pricing power, driven by the value proposition of its integrated financial management and payment solutions. This moat is further protected by the network effects of its large customer base and the barriers to entry for new competitors.
Risk. The bear case against Intuit is centered around its debt-to-equity ratio of 0.33, which, although not alarming, indicates a potential risk if interest rates rise significantly. Additionally, the company's beta of 0.96 suggests it is somewhat sensitive to market fluctuations, which could impact its stock price. A concrete signal that would confirm the bear case is if Intuit's revenue growth rate begins to decelerate significantly, failing to meet its 15.6% growth rate, which would undermine the bull thesis.
Horizon. 1-3 yr $488.17 (analyst consensus (n=32)) — fundamentals + valuation re-rating. 5 yr $714.73 at ~23% CAGR — compounding case rests on the competitive position widening. 10 yr $1,060 if current growth sustains into durable earnings power.
4. ADBE — Adobe Inc. · score 89.7
Software - Application · price $193.41 · 1Y $282.27 · 5Y $413.27 · 10Y $613.06
FCF $10.3b A- · Rev +10.5% B · D/E 0.61 C+ · P/E 11.1x A · PEG 0.54 A-
Why now. The bull case for ADBE rests on its ability to compound growth through its Digital Media segment, which serves a diverse range of customers including photographers, video editors, and content creators, with a $10.3B free cash flow, 11.1 P/E ratio, and 10.5% revenue growth rate. This growth is further supported by a 28.7% profit margin, indicating a strong ability to convert revenue into earnings. The crux of this thesis is the persistence of this growth, driven by the increasing demand for digital media and experience design solutions.
Moat. ADBE's durable edge is rooted in its Digital Experience segment, which provides an integrated platform for brands and businesses to manage customer experiences, supported by a 62.8% return on equity. This high ROE is a result of pricing power from category leadership in digital experience solutions, making it difficult for competitors to quickly replicate. The company's strong position in this segment, combined with its high switching costs, creates a significant barrier to entry for new competitors.
Risk. The bear case against ADBE is centered around its high debt-to-equity ratio of 0.61 and a beta of 1.4, indicating a higher level of volatility compared to the market. Additionally, the company's analyst recommendation mean of 2.63 suggests a 'hold' stance, which could indicate a lack of near-term catalysts for significant upside. A concrete signal that would confirm the bear case is a decline in revenue growth rate, potentially triggered by increased competition in the digital media and experience design spaces.
Horizon. 1-3 yr $282.27 (analyst consensus (n=32)) — fundamentals + valuation re-rating. 5 yr $413.27 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $613.06 if current growth sustains into durable earnings power.
5. LRN — Stride, Inc. · score 89.3
Education & Training Services · price $86.11 · 1Y $99.03 · 5Y $144.98 · 10Y $215.07
FCF $414m C · Rev +17.9% B+ · D/E 0.33 A- · P/E 13.5x A- · PEG 0.48 A
Why now. The bull case for LRN rests on its ability to compound growth through its proprietary online curriculum and educational services, with a 17.9% revenue growth rate and a 13.5 P/E ratio, indicating a 0.48 PEG ratio that suggests the stock is undervalued given its growth prospects. This growth is driven by its technology-based products and services that enable clients to support individualized learning for students. The crux of this thesis is that LRN can maintain its 12.2% profit margin and 18.8% ROE, which would drive further growth and returns for shareholders.
Moat. LRN's durable edge is its integrated package of systems, services, and products that support virtual or blended public schools, which creates a switching cost for its clients and a network effect that makes it harder for competitors to enter the market. The company's 18.8% ROE is driven by its pricing power from category leadership in the online education market, which allows it to maintain its profit margins and invest in further growth initiatives. This moat is protected by the company's proprietary technology and its ability to continuously innovate and improve its products and services.
Risk. The bear case for LRN is that its 0.33 debt-to-equity ratio and 0.08 beta indicate a low level of financial and market risk, but its 13.5 P/E ratio and 1.4 P/S ratio may be elevated given the company's growth prospects and the competitive landscape of the online education market. A concrete signal that would confirm the bear case is if the company's revenue growth rate were to slow down significantly, which would put pressure on its profit margins and ROE, and ultimately lead to a re-rating of the stock.
Horizon. 1-3 yr $99.03 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $144.98 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $215.07 if current growth sustains into durable earnings power.
6. PCTY — Paylocity Holding Corporation · score 89.1
Software - Application · price $100.48 · 1Y $154.16 · 5Y $225.70 · 10Y $334.81
FCF $487m C · Rev +14.8% B+ · D/E 0.11 B+ · P/E 21.5x B+ · PEG 0.82 B+
Why now. The bull case for PCTY rests on its ability to compound growth through its cloud-based human capital management and payroll software solutions, with a 14.8% revenue growth rate and $487m in free cash flow, driven by its time and attendance, scheduling, and time collection offerings, all while maintaining a 16.1% profit margin and 21.9% ROE, which positions it for long-term outperformance, hinging on the persistence of its 21.5 P/E multiple and 0.82 PEG ratio.
Moat. PCTY's durable edge stems from its human resources (HR) solutions, including HR compliance dashboard and HR edge, which create switching costs for its customers, as well as its pricing power from category leadership in the payroll and tax services market, allowing it to maintain a high ROE through pricing power and operational efficiency.
Risk. The bear case against PCTY centers on its debt-to-equity ratio of 0.11, which, although low, could rise if the company takes on more debt to fuel growth, and its beta of 0.51, indicating lower volatility but also potentially lower returns, with the key risk being a contraction in profit margin from its current 16.1% level, which would undermine the bull thesis and send the stock price downward.
Horizon. 1-3 yr $154.16 (analyst consensus (n=19)) — fundamentals + valuation re-rating. 5 yr $225.70 at ~18% CAGR — compounding case rests on the competitive position widening. 10 yr $334.81 if current growth sustains into durable earnings power.
7. ADMA — ADMA Biologics, Inc. · score 88.9
Biotechnology · price $8.72 · 1Y $17.60 · 5Y $25.77 · 10Y $38.23
1Y -53% D · Rev +19.6% B+ · ROE 42.4% A · FCF $108m C
Why now. ADMA Biologics is a compelling growth story, driven by its specialty plasma-derived biologics for immune deficiencies and infectious diseases, with 19.6% revenue growth and a 32.4% profit margin, supported by a $108m free cash flow, positioning it for sustained compounding. The company's IVIG products, such as BIVIGAM and ASCENIV, treat primary humoral immunodeficiency, a critical end market. The bull case rests on ADMA's ability to maintain its 42.4% ROE, driven by pricing power and cost advantages in its plasma collection and manufacturing segments.
Moat. ADMA's durable edge stems from its specialty plasma-derived biologics, particularly its IVIG products, which offer a high barrier to entry due to complex manufacturing processes and stringent regulatory requirements. The company's 42.4% ROE is attributed to its pricing power, driven by category leadership in the IVIG market, and its cost advantages in plasma collection and manufacturing. Competitors cannot quickly replicate ADMA's expertise and scale in these areas, protecting its market position.
Risk. The primary bear case against ADMA is the risk of increased competition in the IVIG market, potentially driven by new entrants or biosimilar products, which could erode the company's 32.4% profit margin. Additionally, ADMA's 1.11 debt-to-equity ratio and 0.73 beta indicate some financial and market risk. A concrete signal that would confirm the bear case is a significant decline in ADMA's ROE or a failure to maintain its revenue growth trajectory.
Horizon. 1-3 yr $17.60 (analyst consensus (n=5)) — fundamentals + valuation re-rating. 5 yr $25.77 at ~24% CAGR — compounding case rests on the competitive position widening. 10 yr $38.23 if current growth sustains into durable earnings power.
8. HRMY — Harmony Biosciences Holdings, Inc. · score 87.9
Biotechnology · price $34.13 · 1Y $44.36 · 5Y $64.95 · 10Y $96.35
1Y +8% C+ · Rev +21.5% A- · ROE 16.0% B+ · FCF $342m C
Why now. The bull case for HRMY rests on its ability to compound growth through its novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy, driven by $342m in free cash flow, a 21.5% revenue growth rate, and a 16.2% profit margin. This growth is further supported by a 13.8 P/E ratio and a 0.18 debt-to-equity ratio, indicating a stable financial foundation. The crux of this thesis is the persistence of this growth, driven by HRMY's commercial-stage pharmaceutical products, particularly WAKIX (pitolisant), which has a novel mechanism of action and is in various stages of clinical trials for other indications.
Moat. HRMY's durable edge is its novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy, which is protected by its intellectual property. This is further supported by its 16% return on equity, driven by pricing power from its category leadership in the treatment of rare neurological diseases. Additionally, HRMY's products, such as WAKIX (pitolisant), have switching costs, as patients are likely to stick with a treatment that is effective, making it difficult for competitors to gain market share.
Risk. The bear case for HRMY is that its growth may decelerate due to increased competition in the treatment of rare neurological diseases, which could lead to a contraction in its 16.2% profit margin. Additionally, HRMY's 0.97 beta indicates that it is highly correlated with the overall market, making it vulnerable to market downturns. If HRMY's revenue growth rate were to slow down significantly, it could confirm the bear case and break the bull thesis.
Horizon. 1-3 yr $44.36 (analyst consensus (n=11)) — fundamentals + valuation re-rating. 5 yr $64.95 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $96.35 if current growth sustains into durable earnings power.
9. NUTX — Nutex Health Inc. · score 87.3
Medical Care Facilities · price $149.10 · 1Y $235.50 · 5Y $344.80 · 10Y $511.48
1Y +25% B+ · Rev +82.4% A · ROE 27.8% A- · FCF $269m C
Why now. The bull case for NUTX rests on its explosive revenue growth of 82.4% in the last fiscal year, driven by its Hospital segment, which offers a range of healthcare services including emergency room care, inpatient care, and behavioral health, with a profit margin of 11% and a market cap of $1.0b, all of which suggests a high-quality compounder with significant room for expansion, and the crux of this thesis is whether NUTX can sustain its fcf of $269m to fuel further growth.
Moat. NUTX's durable edge stems from its Population Health Management segment, which provides management, administrative, and other support services to its affiliated hospitals and physician groups, creating a network effect that makes it difficult for competitors to replicate, and its roe of 27.8% suggests pricing power from category leadership in its micro hospitals and specialty hospitals, which will protect its margins and drive long-term growth.
Risk. The bear case against NUTX is that its debt_to_equity ratio of 0.79 and beta of 2.06 indicate a high level of financial leverage and volatility, which could lead to a sharp decline in the stock price if the company fails to meet its growth expectations, and the concrete signal that would confirm this bear case is a significant decline in its revenue_growth_pct or a increase in its debt_to_equity ratio.
Horizon. 1-3 yr $235.50 (analyst consensus (n=4)) — fundamentals + valuation re-rating. 5 yr $344.80 at ~18% CAGR — compounding case rests on the competitive position widening. 10 yr $511.48 if current growth sustains into durable earnings power.
10. NVDA — NVIDIA Corporation · score 86.5
Semiconductors · price $195.74 · 1Y $298.93 · 5Y $437.67 · 10Y $649.25
FCF $119.1b A · Rev +65.5% A · D/E 0.07 A- · P/E 30.0x B · PEG 0.61 A-
Why now. NVIDIA's dominance in the data center accelerated computing and artificial intelligence solutions market is undeniable, driving phenomenal growth and profitability. With a staggering 65.5% FY YoY revenue growth and an industry-leading 63% profit margin, the company is effectively monetizing the foundational shift to AI infrastructure. The robust $119.1B in free cash flow further underscores its cash-generating power, ensuring continued investment in its core Compute & Networking segment and cementing its lead.
Moat. NVIDIA's durable edge stems from its deep integration of hardware (GeForce GPUs, Quadro/NVIDIA RTX GPUs) and proprietary software platforms, creating a high switching cost ecosystem for its AI solutions and automotive platforms. This technological leadership, particularly in its Compute & Networking segment, enables exceptional pricing power, reflected in its 81.7% ROE, as customers are locked into a performance standard and development environment that competitors struggle to replicate.
Risk. The primary risk for NVIDIA is its elevated valuation, with a TTM P/E of 30 and P/S of 18.7, leaving little room for error if growth in its data center segment decelerates or competition intensifies from custom silicon solutions. Furthermore, the company's high beta of 2.2 suggests significant sensitivity to broader market downturns, which could exacerbate any re-rating. A sustained slowdown in enterprise AI infrastructure spending or a significant erosion of its profit margin would confirm the bear case.
Horizon. 1-3 yr $298.93 (analyst consensus (n=59)) — fundamentals + valuation re-rating. 5 yr $437.67 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $649.25 if current growth sustains into durable earnings power.
11. EXLS — ExlService Holdings, Inc. · score 86.1
Information Technology Services · price $25.22 · 1Y $41.75 · 5Y $61.13 · 10Y $90.68
FCF $297m C · Rev +13.6% B+ · D/E 0.67 C+ · P/E 16.1x A- · PEG 0.84 B+
Why now. ExlService Holdings is a compelling growth story, leveraging its data and AI capabilities to deliver digital operations and analytics-driven services across high-value segments like Insurance and Healthcare. The company's impressive 13.6% FY YoY revenue growth, combined with a healthy 11.7% profit margin and a remarkably low 0.84 PEG ratio, suggests its compounding power is currently undervalued. The crux of the thesis rests on EXLS's ability to continue expanding its analytics-driven solutions, capturing market share in industries undergoing digital transformation.
Moat. EXLS's durable edge stems from its specialized digital operations and analytics-driven services, particularly in complex areas like actuarial and risk analytics and claims management for the Insurance sector. The high 32.3% Return on Equity reflects significant pricing power and deep client integration, creating substantial switching costs for customers who rely on EXLS for mission-critical functions. This expertise in data and AI solutions makes it difficult for competitors to quickly replicate the breadth and depth of its offerings across diverse industry segments.
Risk. The bear case hinges on the intense and rapidly evolving competitive landscape within the data and AI services sector, where new entrants or larger tech players could erode EXLS's market position in areas like digital marketing or underwriting support. The stock's current price of $25.22, hovering near its $25.14 52-week low, suggests market skepticism about its ability to maintain growth momentum or defend margins against aggressive pricing. A sustained deceleration in revenue growth below the current 13.6% or a significant contraction in profit margins would confirm the bear thesis.
Horizon. 1-3 yr $41.75 (analyst consensus (n=8)) — fundamentals + valuation re-rating. 5 yr $61.13 at ~19% CAGR — compounding case rests on the competitive position widening. 10 yr $90.68 if current growth sustains into durable earnings power.
12. FISV — Fiserv, Inc. · score 85.3
Sector n/a · price $47.53 · 1Y $70.00 · 5Y $102.49 · 10Y $152.03
FCF $4.1b B · Rev +9.3% B · D/E n/a · P/E 8.1x A- · PEG n/a
Why now. Fiserv presents an undeniable growth opportunity, trading at a remarkably low P/E of 8.1x despite delivering 9.3% revenue growth year-over-year. The company's ability to generate $4.1 billion in free cash flow against a $25.3 billion market cap highlights its operational efficiency and strong cash generation, which can be reinvested to fuel further expansion in its core payment processing and financial technology segments. This cash compounding capability, driven by persistent demand for digital payment infrastructure, ensures sustained value creation.
Moat. Fiserv's competitive moat is built on the high switching costs inherent in its integrated financial technology solutions, which are deeply embedded into the operations of its institutional clients. Once banks and businesses integrate Fiserv's payment processing and core banking platforms, the operational disruption and cost of migrating to a competitor are substantial, ensuring sticky revenue streams. This deep integration fosters a resilient business model, reflected in its healthy 19.7% profit margin, making it difficult for new entrants to dislodge its market position.
Risk. The bear case for Fiserv centers on its inability to re-accelerate growth in a highly competitive payments landscape, evidenced by the stock trading near its 52-week low of $47.04, a stark contrast to its 52-week high of $175.92. Despite a low P/E, the market's "hold" consensus from 26 analysts suggests skepticism about future upside, implying structural headwinds or increased competition are eroding its growth potential. A sustained period of single-digit revenue growth below 5% for consecutive quarters would confirm that Fiserv's market share is stagnating, justifying its depressed valuation.
Horizon. 1-3 yr $70.00 (analyst consensus (n=26)) — fundamentals + valuation re-rating. 5 yr $102.49 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $152.03 if current growth sustains into durable earnings power.
13. CARG — CarGurus, Inc. · score 84.8
Auto & Truck Dealerships · price $31.03 · 1Y $37.38 · 5Y $54.73 · 10Y $81.20
FCF $293m C · Rev +13.7% B+ · D/E 0.79 B · P/E 16.3x B+ · PEG 0.95 B+
Why now. CarGurus is a high-quality compounder, demonstrating efficient growth through its online automotive platform and expanding product suite like "Digital Deal." Its 13.7% revenue growth is supported by robust free cash flow of $293m, indicating strong operational efficiency, and a compelling PEG ratio of 0.95 suggests the market isn't fully pricing its growth trajectory. The crux is the persistent network effect between car shoppers and its extensive dealer network, driving continued monetization of digital automotive transactions.
Moat. CarGurus' durable edge stems from the powerful network effect of its online automotive marketplace, which connects a large audience of car shoppers with an extensive network of dealers. This two-sided platform creates high switching costs for both consumers and dealers, making it difficult for new entrants to replicate the scale and liquidity. The exceptional 62.9% Return on Equity reflects the company's asset-light model and pricing power derived from its category leadership in efficiently connecting automotive buyers and sellers.
Risk. The primary bear case centers on the highly competitive online automotive market, where established players and new entrants could erode CarGurus' market share or pricing power for dealer subscriptions and advertising. Despite a healthy 15.9% profit margin, the company's relatively high beta of 1.21 indicates sensitivity to broader economic cycles impacting auto sales. A sustained deceleration in the growth of its dealer network or a failure of its "Digital Deal" product to gain significant traction would confirm the bear thesis.
Horizon. 1-3 yr $37.38 (analyst consensus (n=13)) — fundamentals + valuation re-rating. 5 yr $54.73 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $81.20 if current growth sustains into durable earnings power.
14. IT — Gartner, Inc. · score 84.4
Information Technology Services · price $126.63 · 1Y $165.00 · 5Y $241.58 · 10Y $358.36
FCF $1.3b C+ · Rev +3.7% C+ · D/E n/a · P/E 12.5x A- · PEG 0.53 A-
Why now. Gartner is a high-quality compounder trading at a significant discount, with a P/E of 12.5 and an exceptionally low PEG ratio of 0.53, indicating strong earnings growth relative to its valuation. Its robust TTM free cash flow of $1.3b against an $8.5b market cap translates to a compelling FCF yield, suggesting the market is overlooking the stability and cash-generative power of its subscription-based Insights segment. The crux is the market's current undervaluation of a business with consistent, high-margin recurring revenue.
Moat. Gartner's durable edge stems from its Insights segment, which provides "access to published content, data and benchmarks, and direct access to a network of business and technology experts." This creates high switching costs for clients who integrate these "mission-critical priorities" insights into their decision-making, making Gartner's subscription services indispensable and difficult to replicate by competitors.
Risk. The primary concern for Gartner is its modest FY YoY revenue growth of 3.7%, which, combined with the current price of $126.63 sitting just above its 52-week low of $124.25, suggests market apprehension about its growth trajectory or competitive pressures in its Conferences and Consulting segments. A sustained period of single-digit revenue growth, failing to leverage its market position, would confirm the bear case and erode investor confidence.
Horizon. 1-3 yr $165.00 (analyst consensus (n=13)) — fundamentals + valuation re-rating. 5 yr $241.58 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $358.36 if current growth sustains into durable earnings power.
15. EPAM — EPAM Systems, Inc. · score 83.8
Information Technology Services · price $77.37 · 1Y $144.06 · 5Y $210.91 · 10Y $312.87
FCF $544m C+ · Rev +15.4% B+ · D/E 0.08 B+ · P/E 11.1x A · PEG 0.40 A
Why now. EPAM is a fundamentally mispriced growth compounder, trading at a deeply discounted valuation relative to its robust expansion in critical IT services. With a compelling PEG ratio of 0.4 and a meager P/S of 0.7, the market is severely underpricing its 15.4% revenue growth in high-demand areas like digital platform engineering and cloud services. The crux of the thesis is that its consistent ability to capture market share in these essential technology segments will drive a significant re-rating.
Moat. EPAM's durable edge stems from the high switching costs inherent in its core offerings of digital platform engineering and software development services. Clients integrating complex 'cloud services,' 'data, analytics and artificial intelligence,' and 'cybersecurity' solutions become deeply embedded, making a transition to a new provider costly and disruptive. Furthermore, its 'integrated engineering practices and smart automation services' suggest a specialized, efficient delivery model that is difficult for competitors to quickly replicate, fostering long-term client stickiness.
Risk. The primary bear case centers on EPAM's high sensitivity to a cyclical downturn in enterprise IT spending, which could severely impact demand for its 'digital platform engineering and software development services.' The stock's elevated Beta of 1.4 and current price of $77.37, barely above its 52-week low of $73.06, highlight its vulnerability to broader economic headwinds and market skepticism. A sustained deceleration in its 15.4% revenue growth or a material compression of its 7% profit margin would confirm the bear case, signaling a loss of pricing power or demand.
Horizon. 1-3 yr $144.06 (analyst consensus (n=18)) — fundamentals + valuation re-rating. 5 yr $210.91 at ~22% CAGR — compounding case rests on the competitive position widening. 10 yr $312.87 if current growth sustains into durable earnings power.
16. DXCM — DexCom, Inc. · score 83.5
Medical Devices · price $68.65 · 1Y $85.24 · 5Y $124.80 · 10Y $185.13
1Y -18% D · Rev +15.6% B+ · ROE 31.5% A · FCF $1.4b C+
Why now. DexCom's expansion into the broader diabetes and metabolic health market, particularly with Stelo for non-insulin users, is poised to drive sustained revenue and profit growth. With a robust 15.6% FY YoY revenue growth and an impressive 31.5% Return on Equity, the company demonstrates strong operational efficiency. The current $1.4b in TTM free cash flow provides ample capital to fuel further innovation and market penetration, ensuring compounding returns as CGM adoption widens.
Moat. DexCom's durable edge stems from its integrated continuous glucose monitoring (CGM) systems like Dexcom G7 and Dexcom G6, which create high switching costs for patients and healthcare providers. Direct marketing to endocrinologists, physicians, and diabet builds deep relationships, while the Dexcom Share and Dexcom Follow applications enhance user stickiness. This ecosystem and critical role in diabetes treatment decisions contribute to a superior 31.5% ROE, reflecting strong pricing power and customer retention.
Risk. The primary risk for DexCom lies in potential competitive disruption or market saturation within the continuous glucose monitoring space, which could pressure its premium valuation. With a P/E TTM of 29.5 and a beta of 1.44, the stock is sensitive to any deceleration in its 15.6% revenue growth. A sustained decline in the adoption rates for key products like Dexcom G7 or Stelo, leading to a contraction in the 19.3% profit margin, would signal a fundamental weakening of the bull thesis.
Horizon. 1-3 yr $85.24 (analyst consensus (n=25)) — fundamentals + valuation re-rating. 5 yr $124.80 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $185.13 if current growth sustains into durable earnings power.
17. VEEV — Veeva Systems Inc. · score 83.5
Health Information Services · price $158.08 · 1Y $244.59 · 5Y $358.11 · 10Y $531.23
FCF $1.7b C+ · Rev +16.3% B+ · D/E 0.01 A- · P/E 28.0x B · PEG 0.73 A-
Why now. Veeva Systems is a high-quality compounder, delivering mission-critical cloud software that underpins the global life sciences industry. Its specialized platforms like Veeva Commercial Cloud and Veeva Data Cloud drive robust growth, evidenced by a 16.3% FY YoY revenue increase and a stellar 28.4% profit margin. With a PEG ratio of just 0.73, Veeva offers growth at a reasonable price, as its deep entrenchment in pharmaceutical and biotechnology operations ensures continued demand for its integrated solutions.
Moat. Veeva's moat stems from the deep integration and specialized nature of its cloud-based software within the highly regulated life sciences industry. Products like Veeva Vault CRM Suite and Veeva PromoMats become indispensable to pharmaceutical and biotechnology companies, creating high switching costs once embedded in their commercial and medical operations. Furthermore, data platforms such as Veeva OpenData and Veeva Link benefit from network effects, enhancing their value as more industry participants adopt them, making it difficult for generalist competitors to replicate.
Risk. The bear case centers on Veeva's premium valuation and its concentrated exposure to the life sciences sector, which could face cyclical headwinds or increased regulatory scrutiny. Despite its growth, a P/E of 28 is still demanding, especially given the stock's significant drop from its 52-week high of $310.50, indicating sensitivity to growth expectations. A concrete signal confirming the bear case would be a sustained decline in its 16.3% revenue growth rate, suggesting market saturation or intensified competition in its core Veeva Commercial Cloud or Data Cloud segments.
Horizon. 1-3 yr $244.59 (analyst consensus (n=27)) — fundamentals + valuation re-rating. 5 yr $358.11 at ~18% CAGR — compounding case rests on the competitive position widening. 10 yr $531.23 if current growth sustains into durable earnings power.
18. YELP — Yelp Inc. · score 82.4
Internet Content & Information · price $22.92 · 1Y $26.50 · 5Y $38.80 · 10Y $57.56
FCF $281m C · Rev +3.7% C+ · D/E 0.25 A- · P/E 10.5x A- · PEG 0.57 A-
Why now. Yelp is a highly profitable platform connecting consumers with local businesses, trading at a significant discount to its intrinsic value. With a remarkably low P/E of 10.5 and an even more compelling PEG Ratio of 0.57, the market is severely underpricing its consistent free cash flow generation of $281m (TTM). The crux of the thesis lies in the market eventually recognizing the durable profitability of its advertising products across diverse categories like home, auto, and professional services.
Moat. Yelp's durable edge stems from a powerful network effect between consumers seeking local services and businesses needing visibility across its extensive categories, including restaurants, beauty, and health. This platform, reinforced by its free and paid advertising products like cost-per-click and multi-location ads, creates significant switching costs for businesses embedded in its ecosystem. The impressive ROE of 22% is a direct result of this platform's pricing power and efficient capital deployment, as it leverages existing user data and business relationships to drive advertising revenue.
Risk. The primary bear case against Yelp centers on its decelerating growth profile in an intensely competitive local advertising market. Despite its profitability, the company's revenue growth of only 3.7% (FY YoY) suggests that its platform may be struggling to expand its user or advertiser base meaningfully. Skeptics would argue that competition from larger tech players or niche vertical platforms could continue to cap its upside, making its current valuation a 'value trap' rather than an undervalued growth story. A sustained inability to grow its Yelp Connect or RepairPal network offerings would confirm this bear thesis.
Horizon. 1-3 yr $26.50 (analyst consensus (n=8)) — fundamentals + valuation re-rating. 5 yr $38.80 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $57.56 if current growth sustains into durable earnings power.
19. META — Meta Platforms, Inc. · score 82.3
Internet Content & Information · price $542.87 · 1Y $827.32 · 5Y $1,211 · 10Y $1,797
FCF $48.3b A · Rev +22.2% A- · D/E 0.36 B+ · P/E 19.7x B · PEG 0.81 B+
Why now. Meta Platforms' Family of Apps (FoA) segment is a high-quality compounder, delivering robust free cash flow growth at an attractive valuation. With revenue growth of 22.2% and a strong profit margin of 32.8%, the company's PEG ratio of 0.81 signals significant undervaluation for its growth profile. The thesis rests on Meta's ability to continue monetizing its vast global user base across Facebook, Instagram, and Messenger, efficiently converting revenue into shareholder returns.
Moat. The core competitive advantage stems from the powerful network effects embedded within its Family of Apps (FoA), including Facebook, Instagram, and Messenger, which connect billions globally. This extensive user base creates high switching costs and a self-reinforcing loop, allowing Meta to command significant pricing power in digital advertising. This structural advantage is clearly reflected in its exceptional ROE of 29%, demonstrating superior capital efficiency and profitability that is difficult for competitors to replicate.
Risk. The primary bear case hinges on Meta's high market sensitivity, evidenced by its beta of 1.23, making it susceptible to broader market downturns and investor sentiment shifts. Furthermore, continued significant investment into Reality Labs (RL) without a clear, near-term path to profitability could suppress overall earnings growth and capital efficiency. A sustained deceleration in user growth or engagement across its core Family of Apps, signaling a weakening of its foundational network effects, would be the critical signal confirming the bear thesis.
Horizon. 1-3 yr $827.32 (analyst consensus (n=59)) — fundamentals + valuation re-rating. 5 yr $1,211 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $1,797 if current growth sustains into durable earnings power.
20. RMD — ResMed Inc. · score 82.3
Medical Instruments & Supplies · price $198.60 · 1Y $260.60 · 5Y $381.54 · 10Y $566.00
1Y -23% D · Rev +9.8% B · ROE 23.4% A- · FCF $1.8b C+
Why now. Medical Instruments & Supplies · market cap $28.8b. Down 32% from 52-week high of $293.81 — deep drawdown territory. 15 sell-side analysts rate this a Buy with a mean 1-yr target of $260.60 (implying +31% upside).
Moat. Net margin 27% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 23% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 115% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 32% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $260.60 (analyst consensus (n=15)) — fundamentals + valuation re-rating. 5 yr $381.54 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $566.00 if current growth sustains into durable earnings power.
21. CVSA — Covista Inc. · score 81.9
Education & Training Services · price $124.16 · 1Y $156.25 · 5Y $197.26 · 10Y $252.98
FCF $336m C · Rev +12.9% B+ · D/E 0.54 B+ · P/E 18.1x B+ · PEG 0.88 B+
Why now. Education & Training Services · market cap $4.2b. Down 21% from 52-week high of $156.26 — deep drawdown territory. Revenue growing +13%, comfortably above the S&P median. PEG 0.88 — paying under fair value for the growth rate. 4 sell-side analysts publish a mean 1-yr target of $156.25 (implying +26% upside).
Moat. Net margin 12% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 17% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 144% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon. 1-3 yr $156.25 (analyst consensus (n=4)) — multiple re-rating thesis requires a catalyst. 5 yr $197.26 at ~10% CAGR — dividend + buyback compounding. 10 yr $252.98 if the moat survives secular pressure.
22. MELI — MercadoLibre, Inc. · score 81.9
Internet Retail · price $1619.25 · 1Y $2,217 · 5Y $3,246 · 10Y $4,815
1Y -35% D · Rev +34.3% A · ROE 26.4% A- · FCF $11.8b A-
Why now. Internet Retail · market cap $82.1b. Down 39% from 52-week high of $2645.22 — deep drawdown territory. Revenue growing +34% — in hypergrowth territory. 24 sell-side analysts rate this a Buy with a mean 1-yr target of $2,217 (implying +37% upside).
Moat. ROE 26% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Free cash flow runs well ahead of reported net income — non-cash charges (depreciation, intangible amortization) are holding down GAAP earnings while cash generation stays strong. $82.1b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk. Down 39% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trailing P/E 43x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. E-commerce competition — Amazon, Walmart, Shein, and Temu have each forced the rest of the category to compete on price, fulfillment speed, or assortment; sustaining margins requires one of those being structurally defended.
Horizon. 1-3 yr $2,217 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $3,246 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $4,815 if current growth sustains into durable earnings power.
23. PRDO — Perdoceo Education Corporation · score 81.4
Education & Training Services · price $32.98 · 1Y $35.62 · 5Y $44.97 · 10Y $57.67
FCF $225m C · Rev +24.2% A- · D/E 0.12 A- · P/E 12.6x A- · PEG 0.70 A-
Why now. Education & Training Services · market cap $2.1b. 14% off the 52-week high of $38.50. Revenue growing +24%, comfortably above the S&P median. PEG 0.70 — paying under fair value for the growth rate.
Moat. Net margin 20% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 17% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 132% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon. 1-3 yr $35.62 (structural (no analyst coverage)) — multiple re-rating thesis requires a catalyst. 5 yr $44.97 at ~6% CAGR — dividend + buyback compounding. 10 yr $57.67 if the moat survives secular pressure.
24. EPAC — Enerpac Tool Group Corp. · score 79.6
Specialty Industrial Machinery · price $37.07 · 1Y $40.04 · 5Y $50.54 · 10Y $64.82
FCF $111m C · Rev +4.6% C+ · D/E 0.46 B+ · P/E 23.3x B+ · PEG 0.34 A
Why now. Specialty Industrial Machinery · market cap $2.0b. 19% off the 52-week high of $45.54. PEG 0.34 — paying under fair value for the growth rate.
Moat. Net margin 14% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 21% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 129% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon. 1-3 yr $40.04 (structural (no analyst coverage)) — multiple re-rating thesis requires a catalyst. 5 yr $50.54 at ~6% CAGR — dividend + buyback compounding. 10 yr $64.82 if the moat survives secular pressure.
25. FIVE — Five Below, Inc. · score 79.2
Specialty Retail · price $186.59 · 1Y $261.57 · 5Y $330.23 · 10Y $423.51
FCF $505m C+ · Rev +22.9% A- · D/E 0.86 B · P/E 23.6x B · PEG 0.98 B+
Why now. Specialty Retail · market cap $10.3b. Down 26% from 52-week high of $251.63 — deep drawdown territory. Revenue growing +23%, comfortably above the S&P median. PEG 0.98 — paying under fair value for the growth rate. 21 sell-side analysts rate this a Buy with a mean 1-yr target of $261.57 (implying +40% upside).
Moat. ROE 19% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 115% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon. 1-3 yr $261.57 (analyst consensus (n=21)) — multiple re-rating thesis requires a catalyst. 5 yr $330.23 at ~12% CAGR — dividend + buyback compounding. 10 yr $423.51 if the moat survives secular pressure.
26. WLDN — Willdan Group, Inc. · score 78.2
Engineering & Construction · price $78.93 · 1Y $85.24 · 5Y $107.62 · 10Y $138.02
FCF $43m C- · Rev +20.5% A- · D/E 0.22 A- · P/E 21.2x B+ · PEG 0.48 A
Why now. Engineering & Construction · market cap $1.2b. Down 42% from 52-week high of $137.00 — deep drawdown territory. Revenue growing +20%, comfortably above the S&P median. PEG 0.48 — paying under fair value for the growth rate.
Moat. ROE 18% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately.
Risk. Down 42% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $85.24 (structural (no analyst coverage)) — multiple re-rating thesis requires a catalyst. 5 yr $107.62 at ~6% CAGR — dividend + buyback compounding. 10 yr $138.02 if the moat survives secular pressure.
27. DECK — Deckers Outdoor Corporation · score 78.1
Footwear & Accessories · price $102.59 · 1Y $126.86 · 5Y $160.15 · 10Y $205.39
FCF $1.1b C+ · Rev +9.8% B · D/E 0.15 A · P/E 14.6x A- · PEG 1.32 B
Why now. Footwear & Accessories · market cap $14.2b. 19% off the 52-week high of $126.50. 21 sell-side analysts rate this a Buy with a mean 1-yr target of $126.86 (implying +24% upside).
Moat. Net margin 19% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 41% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 107% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon. 1-3 yr $126.86 (analyst consensus (n=21)) — multiple re-rating thesis requires a catalyst. 5 yr $160.15 at ~9% CAGR — dividend + buyback compounding. 10 yr $205.39 if the moat survives secular pressure.
28. HURN — Huron Consulting Group Inc. · score 78.1
Consulting Services · price $92.21 · 1Y $184.25 · 5Y $269.76 · 10Y $400.17
1Y -28% D · Rev +11.7% B · ROE 26.1% A- · FCF $124m C
Why now. Consulting Services · market cap $1.5b. Down 51% from 52-week high of $186.78 — deep drawdown territory. Revenue growing +12%, comfortably above the S&P median. 4 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $184.25 (implying +100% upside).
Moat. ROE 26% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 119% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. D/E 2.24 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Down 51% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $184.25 (analyst consensus (n=4)) — fundamentals + valuation re-rating. 5 yr $269.76 at ~24% CAGR — compounding case rests on the competitive position widening. 10 yr $400.17 if current growth sustains into durable earnings power.
29. NFLX — Netflix, Inc. · score 78.1
Entertainment · price $70.90 · 1Y $114.15 · 5Y $167.12 · 10Y $247.91
1Y -45% D · Rev +15.9% B+ · ROE 43.0% A · FCF $11.9b A-
Why now. Entertainment · market cap $298.5b. Down 47% from 52-week high of $134.12 — deep drawdown territory. Revenue growing +16%, comfortably above the S&P median. 44 sell-side analysts rate this a Buy with a mean 1-yr target of $114.15 (implying +61% upside).
Moat. Net margin 29% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 43% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. $298.5b market cap places it among the largest companies in the sector — distribution, R&D, and customer-acquisition costs amortize across a base peers can't replicate.
Risk. Down 47% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Beta 1.49 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return.
Horizon. 1-3 yr $114.15 (analyst consensus (n=44)) — fundamentals + valuation re-rating. 5 yr $167.12 at ~19% CAGR — compounding case rests on the competitive position widening. 10 yr $247.91 if current growth sustains into durable earnings power.
30. DV — DoubleVerify Holdings, Inc. · score 77.7
Advertising Agencies · price $9.95 · 1Y $13.06 · 5Y $19.12 · 10Y $28.36
1Y -30% D · Rev +13.9% B+ · ROE 5.1% C+ · FCF $135m C
Why now. Advertising Agencies · market cap $1.5b. Down 41% from 52-week high of $16.82 — deep drawdown territory. Revenue growing +14%, comfortably above the S&P median. PEG 0.62 — paying under fair value for the growth rate. 17 sell-side analysts rate this a Buy with a mean 1-yr target of $13.06 (implying +31% upside).
Moat. Free cash flow runs well ahead of reported net income — non-cash charges (depreciation, intangible amortization) are holding down GAAP earnings while cash generation stays strong.
Risk. Down 41% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trailing P/E 30x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. ROE 5% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.
Horizon. 1-3 yr $13.06 (analyst consensus (n=17)) — fundamentals + valuation re-rating. 5 yr $19.12 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $28.36 if current growth sustains into durable earnings power.
Methodology footnote
Every pick on this list comes out of the same quality-growth model — one 0–100 score blending quality, growth, and value — applied to every US-listed common stock with a market cap above $1B. Each pick's score breakdown is auditable from the home page — click the ticker on the rankings page to see exactly which grades produced the number. Not investment advice. See terms for full disclosures.